{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:57:27Z","timestamp":1758776247809,"version":"3.44.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This case report aims to evaluate the efficacy of zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi), in achieving durable disease control for patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who have experienced disease progression on ibrutinib, a first-generation BTKi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A patient with CLL\/SLL who developed resistance to ibrutinib was treated with zanubrutinib. The patient\u2019s clinical response, including disease progression, symptom control, and adverse effects, was monitored over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patient demonstrated significant and durable disease control following the initiation of zanubrutinib therapy. The treatment was well-tolerated, with no severe adverse effects reported, suggesting that zanubrutinib may be an effective therapeutic option for ibrutinib-resistant CLL\/SLL patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The findings from this case report suggest that zanubrutinib may provide a viable treatment option for patients with CLL\/SLL who have progressed on ibrutinib. Further studies and clinical trials are warranted to confirm these observations and to explore the broader applicability of zanubrutinib in managing ibrutinib-resistant CLL\/SLL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1671124","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:42Z","timestamp":1758773862000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhenhui","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhua","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuena","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2466101","article-title":"Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy","volume":"66","author":"Gruessner","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"J ChemMedChem"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"RESONATE-2 investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134280","article-title":"Efficacy and safety of zanubrutinib in patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del (17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell Malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16020027","article-title":"Current therapeutic sequencing in chronic lymphocytic leukemia","volume":"16","author":"Mouhssine","year":"2024","journal-title":"Hematol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2973-2","article-title":"Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib","volume":"96","author":"Kaur","year":"2017","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"s266","DOI":"10.1016\/S2152-2650(22)01324-6","article-title":"CLL-115 First interim analysis of ALPINE  : Results of a Phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"22","author":"Hillmen","year":"2022","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136990","article-title":"Ibrutinib and obinutuzumab in CLL: MRD responses sustained for several years with deepest MRD depletion in patients with> 1 year prior ibrutinib exposure","volume":"136","author":"Rawstron","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1671124\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:44Z","timestamp":1758773864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1671124\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1671124"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1671124","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1671124"}}